Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

Vaccibody – now Nykode – in vaccine deal with Regeneron

Nykode has signed a multi-target a license and collaboration agreement covering five programmes on vaccines for cancer and infectiuous disease. The...

From make-up to jet fuel: Breakthrough for Global Bioenergies

What does eye shadow have to do with biojet fuel? A lot, if you ask Global Bioenergies, a Evry-based biotech that is known for having developed a...

Vifor buys out one-drug wonder Sanifit

The drug candidate, SNF472, is a selective calcification inhibitor with a novel mechanism of action. It is being developed for the treatment of...

Quell raises US$156m for Treg cell therapy programme

The financing round was co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company...

LSP and EQT merge to create top-10 investment firm

The LSP network in the life sciences community has been developed over 33 years and is complementary to EQT’s global healthcare advisory network....

Novo Holdings invests €86m in 21st.BIO

Established in 2020, 21st.BIO has been founded with a mission to support bioindustrial companies globally in upscaling from molecule innovation to...

EU orders up Valneva’s inactivated Covid-19 vaccine

The European Commission has approved an agreement with Valneva under which the French vaccine maker would supply up to 60 million doses of VLA2001,...